Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar
Sandoz Inc. is appealing after a Virginia federal court ruled it should have brought claims accusing Amgen of blocking competition for the Enbrel biosimilar in a previous patent dispute, according to...To view the full article, register now.
Already a subscriber? Click here to view full article